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Abstract
Background: Suppression of immune system in treated cancer patients may lead to secondary infections that
obviate the need of antibiotics. In the present study, an attempt was made to understand the occurrence of
secondary infections in immuno-suppressed patients along with herbal control of these infections with the
following objectives to: (a) isolate the microbial species from the treated oral cancer patients along with the
estimation of absolute neutrophile counts of patients (b) assess the in vitro antimicrobial activity medicinal plants
against the above clinical isolates.
Methods: Blood and oral swab cultures were taken from 40 oral cancer patients undergoing treatment in the
radiotherapy unit of Regional Cancer Institute, Pt. B.D.S. Health University,
Rohtak, Haryana. Clinical isolates were identified by following general microbiological, staining and biochemical
methods. The absolute neutrophile counts were done by following the standard methods. The medicinal plants
selected for antimicrobial activity analysis were Asphodelus tenuifolius Cav., Asparagus racemosus Willd., Balanites
aegyptiaca L., Cestrum diurnum L., Cordia dichotoma G. Forst, Eclipta alba L., Murraya koenigii (L.) Spreng. , Pedalium
murex L., Ricinus communis L. and Trigonella foenum graecum L. The antimicrobial efficacy of medicinal plants was
evaluated by modified Kirby-Bauer disc diffusion method. MIC and MFC were investigated by serial two fold
microbroth dilution method.
Results: Prevalent bacterial pathogens isolated were Staphylococcus aureus (23.2%), Escherichia coli (15.62%),
Staphylococcus epidermidis (12.5%), Pseudomonas aeruginosa (9.37%), Klebsiella pneumonia (7.81%), Proteus mirabilis
(3.6%), Proteus vulgaris (4.2%) and the fungal pathogens were Candida albicans (14.6%), Aspergillus fumigatus
(9.37%). Out of 40 cases, 35 (87.5%) were observed as neutropenic. Eight medicinal plants (A. tenuifolius, A.
racemosus, B. aegyptiaca, E. alba, M. koenigii, P. murex R. communis and T. foenum graecum) showed significant
antimicrobial activity (P < .05) against most of the isolates. The MIC and MFC values were ranged from 31 to 500
μg/ml. P. aeruginosa was observed highest susceptible bacteria (46.6%) on the basis of susceptible index.
Conclusion: It can be concluded that treated oral cancer patients were neutropenic and prone to secondary
infection of microbes. The medicinal plant can prove as effective antimicrobial agent to check the secondary
infections in treated cancer patients.
Background
Over the past decade, advances in the cancer treatment
field have been counterbalanced by a rising number of
immunosuppressed patients with a multitude of new
risk factors for infection [1]. Cancer patients may be
immunocompromised due to multiple factors such as
chemotherapy, radiotherapy, impairment of normal
leukocyte function, or use of corticosteroids [2]. As well
as the infections complications remain an important
cause of mortality and morbidity between these febrile
neutropenic cancer cases [3,4]. They are highly suscepti-
ble to almost any type of infection, especially bacterial
and fungal infection [5].
Same side the heavy antimicrobial usage particularly in
high-risk cancer patients create selection pressures that
lead to the emergence of resistant micro-organisms [6].
For instance, many cancer centers have reported an
increase in quinolone resistant bacteria (primarily
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patients receiving quinolone prophylaxis [6-8]. The use
of very broad spectrum agents such as the carbapenems
has been associated with the selection of multidrug-
resistant (MDR) in Stenotrophomonas maltophilia and
Pseudomonas aeruginosa [9-11]. Therefore the increase
in antibiotic resistance activity is posing an ever increas-
ing therapeutic problem in cancer case and the ways by
which bacteria overcome drug action are many and var-
ied, ranging from intrinsic impermeability to acquired
resistance [12-14]. In light of the evidence of rapid
spread of resistant clinical isolates, the need to find new
antimicrobial agent is of paramount importance for the
treatment of infectious diseases in cancer cases.
Researchers are increasingly turning their attention to
the medicinal plants and it is estimated that, plant mate-
rials are present in, or have provided the models for 25-
50% Western drugs [15,16]. Many commercially proven
drugs used in modern medicine was initially used in
crude form in traditional or folk healing practices, or for
other purposes that suggested potentially useful biologi-
cal activity. Because the primary benefits of using plant
derived medicines are that they are relatively safer than
synthetic alternatives, offering profound therapeutic ben-
efits and more affordable treatment [17]. As well as the
scarcity of infective disease in wild plants is in itself an
indication of the successful defense mechanism devel-
oped by them. The defenses mechanisms of the plants
may be due to production of enormous variety of small
molecules generally classified as ‘Phytoalexins’.P h y t o a -
lexins are “low molecular weight (MW < 500), anti-
microbial compounds that are both synthesized and
accumulated in plants after exposure to microorganisms
or abiotic agents”. Phytoalexins structural spaces contain
terpenoids, glycosteroids, flavonoids and polyphenols
and these biologically active compounds supposed to
exhibit antimicrobial properties [18-20].
Since time immemorial, the traditional medicinal prac-
tices have been known for the treatment of various ail-
ments in India. The medicinal plants were selected in
this study based on their common uses in Indian tradi-
tional systems of medicine [21-27]. Keeping in view, the
infectious diseases in oral cancer patients it was impor-
tant to investigate whether the Indian indigenous plants
have any antimicrobial activity against clinical isolates of
oral cancer cases. So the present investigation evaluates
the infection in immunocompromised oral cancer cases
and in vitro antimicrobial activity of crude extracts of
ten medicinal plants (Asphodelus tenuifolius Cav.,
Asparagus racemosus Willd., Balanites aegyptiaca L.,
Cestrum diurnum L., Cordia dichotoma G. Forst, Eclipta
alba L., Murraya koenigii (L.) Spreng., Pedalium murex
L., Ricinus communis L. and Trigonella foenum graecum
L.) against these clinical isolates.
Materials and methods
Blood and oral swab cultures were taken from 40 oral can-
cer patients undergoing treatment in the radiotherapy unit
of Regional Cancer Institute, Pt. B.D.S. Health University,
Rohtak, Haryana (September 2008 to September 2009).
These patients were under different treatment protocol i.e.,
radiotherapy, chemotherapy and radio-chemotherapy both
together. The present study was approved by Institutional
Human Ethics Committee of the university (M.D. Univer-
sity, Rohtak) and written consent was also taken from the
patients. The blood samples (5 ml) were collected from
central venous catheter and peripheral vein of the patients
at the onset of fever (before the prescription of antibiotics).
Blood samples were then transferred in culture bottles of
brain heart infusion broth (Hi Media, Mumbai, India). Bot-
tles were incubated at 36.7°C for 7 days. Bottles showing
positive growth index were Gram stained and sub cultured
on sheep blood agar, sabourad dextrose agar, MacConkey
agar and on nutrient agar plates all media were taken from
Hi Media, Mumbai, India. These plates were aerobically
incubated for 24-48 h at 37°C for isolation of bacterial
pathogens and for 24-72 h at 30°C in B.O.D. incubator for
fungal pathogenic species isolation. Oral swab were taken
by gently rubbing a sterile cotton swab over the labial
mucosa, tongue and cancerous lesion [28]. Oral swab were
taken at the onset of fever (before the prescription of anti-
biotics). The swabs were incubated in sheep blood agar,
saboured dextrose agar, macconkey agar, nutrient agar, and
other selective media for primary isolation of the patho-
gens. These plates were then aerobically incubated for 24-
48 h at 37°C for bacterial pathogens isolation and for 24-72
h at 30°C in B.O.D. incubator for fungal species isolation.
When growth was appeared on sub cultured plates of
blood and oral swab, all bacterial pathogens were identified
by standard microbiological and biochemical procedures.
These biochemical tests include carbohydrates fermenta-
tion test, urease test, oxidase test, haemolysis of blood, cat-
alase test, motility test and growth of pathogens on specific
media etc. [29-32]. A preliminary examination of fungal
colony on SDA was done through Gram-stained smear,
formation of germ tube, study of micro morphology, mor-
phology on KOH stained smear, assimilation of carbon and
nitrogen [29-32]. All isolated pathogens were compared
with MTCC standard strains like S. aureus with MTCC 96
strain, S. epidermidis MTCC 435 strain, P. vulgaris MTCC
426 strain, P. mirabilis MTCC 425 strain, E. coli MTCC
443 strain, K. pneumonia MTCC 109 strain, P. aeruginosa
MTCC 741 strain, C. albicans 3017 strain and A. fumigatus
2550 strain respectively.
Absolute neutrophile count
The absolute neutrophile count (ANC) was done by
multiplying the total WBC count by percentage of neu-
trophils (segmented + band) [5].
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Neutropenia: When ANC was less than 500 (sever risk
of infection).
N o nn e u t r o p e n i a :W h e nA N Cw a sm o r et h a n5 0 0
(moderate risk of infection).
Collection of Plant Material
The fruits of A. tenuifolius, fresh tubers of A. racemosus,
mature fruits of B. aegyptiaca, aerial part of C. diurnum,
mature fruits of C. dichotoma,w h o l ep l a n to fE. alba,
mature fruits P. murex, leaves of M. koenigii,s e e d so fR.
communis and leaves of T. foenum graecum were col-
lected (October 2008 to December 2009) from different
regions of Haryana. The collected plants were identified
in the laboratory. Comparison of flora was also made
according to different references concerning with the
medicinal plants of Haryana and adjoining areas [33-36].
The voucher specimens were deposited in the herbar-
ium of Genetics Department, M. D. University, Rohtak.
All plant parts were dried at room temperature. The
dried parts were pounded to fine powder and extracted
in different solvents according to their increasing polar-
ity (Petroleum ether, benzene, chloroform, acetone,
methanol and aqueous) for 24 h in Soxhlet apparatus.
The solvents were recovered with the help of rotary eva-
p o r a t o ra t4 0 ° C .T h eq u a n t i t yo fo b t a i n e dd r i e dp l a n t
material varies from 100 gm to 500 gm. The dried
extracts were lyophilized in lypholyser. The lyophilized
extracts were stored in air tight tubes at 4°C for further
anti-microbial analysis.
Assay for antimicrobial testing
Isolated test bacteria were grown overnight on nutrient
agar plates and fungi were grown on sabouraud dextrose
agar plates. Bacterial inoculums were prepared from
overnight grown cultures (24 h) in peptone water (Hi
Media, Mumbai, India), and the turbidity was adjusted
equivalent to 0.5 McFarland units (approximately 10
8
CFU/ml for bacteria and fungi inoculums turbidity was
equivalent at 10
5 or 10
6 CFU/ml). The microorganisms
were inoculated into peptone water and incubated at 35
± 2°C for 4 h. The positive control was taken streptomy-
cin (10 μg/ml) for antibacterial activity and ketocanozole
(10 μg/ml) for antifungal activity. The DMSO added
disc was taken as negative control to determine possible
inhibitory activity of the dilutant of extract. The suscept-
ibilities of the isolated pathogens were determined by
the modified Kirby-Bauer disc diffusion method with
Muller Hinton agar plates [37]. Aliquots of inoculums
were spread over the surface of agar plates with a sterile
glass spreader. To test the antimicrobial activity all
extracts were dissolved in DMSO to make a final con-
centration of 200 mg/ml. 20 μl of each extract was
soaked separately into sterile discs (Hi Media, Mumbai,
India), and the discs were dried in oven for 4 hours at
35°C. These discs were placed on Muller Hinton agar
plates, previously swabbed with the bacterial and fungal
inoculum. These plates were incubated for a period of
24 h at 37°C in incubator for bacteria and at 30°C for
24-48 h in B.O.D incubator for fungi. Each experiment
was done in triplicate and mean values were taken.
Antimicrobial activity was measured in the diameter
(mm) of the clear inhibitory zone formed around the
disc.
Minimum inhibitory concentration (MIC) and Minimum
fungicidal concentration (MFC)
The MIC and MFC values of extracts were determined
based on a microbroth dilution method in 96 multi-well
microtitre plates with slight modifications [38]. The
crude plant extracts were first diluted to the highest
concentration, 40000 to 625 μg/ml), to be tested, and 50
μl of normal saline was distributed from the second to
the ninth well. A volume of 50 μl from each extracts
was pipetted into the first test well of each microtitre
line which acts as sterility control, and then 50 μlo f
scalar dilution of plant extract was transferred from the
second to the ninth well. To each well was added 10 μl
of resazurin indicator solution (prepared by dissolving a
270 mg tablet in 40 ml of sterile distilled water). Using
ap i p e t t e3 0μl of Muller Hinton broth was added to
each well to ensure that the final volume was of single
strength of the normal saline. Finally, 10 μlo ft h eb a c -
terial suspensions were added to each well. In each
plate, a column with a broad-spectrum antibiotic was
used as the positive control (streptomycin in serial dilu-
tion 40000 to 625 μg/ml).
The plates were wrapped loosely with cling film to
ensure that bacterium did not become dehydrated, and
were prepared in triplicate. Subsequently, they were
placed in an incubator at 37°C for 24 h. Any color
change from purple to pink or to colorless was recorded
as positive.
The lowest concentration at which the color change
occurred was taken as the MIC and MFC value. The
average of three values was calculated to determine the
MIC and MFC of the test material.
Preliminary phytochemical analysis
The qualitative preliminary phytochemical analyses of
the crude extracts of all plants part isolated from differ-
ent solvents were performed by following standard
methods [39,40].
Statistical analysis
Each parameter was tested in triplicate. The values were
expressed as mean ± standard deviation (SD). The
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mine the significant differences among all columns
against control and the P value < .05 was considered as
significant. All statistical analysis was performed using
Graph Pad Prism version 5.03 software.
Quantitative evaluation of antimicrobial activity
% of extractive value:
% of Extracted Value =
Extract Obtained × 100
Weight of powdered sample
Percent activity: The percent activity demonstrates the
total anti- microbial potency of particular extract. It
shows number of microbes found susceptible to one
particular extract [41].
Activity (% ) =
100 × no. of susceptible strains to a speciﬁc extract
totaln o. of tested microbial strains
Bacterial susceptible index (BSI): BSI is used to com-
pare the relative susceptibility between bacterial strains.
BSI valves ranges from 0 (resistance to all samples) to
100 (susceptible to all extract [41].
BSI =
100 × no. of extracts effective against each bacterial strain
no. of total samples
Results
In the present study the predominant bacterial patho-
gens isolated were Staphylococcus aureus (23.2%),
Escherichia coli (15.62%), Staphylococcus epidermidis
(12.5%), Pseudomonas aeruginosa (9.37%), Klebsiella
pneumonia (7.81%), Proteus mirabilis (3.6%), Proteus
vulgaris (4.2%) and the fungal pathogens were Candida
albicans (14.6%), Aspergillus fumigatus (9.37%). On the
basis of absolute neutrophile count it was observed that
out of 40 cases, 35 (87.5%) were neutropenic. The
extracts of ten medicinal plants were prepared in the
petroleum ether, benzene, chloroform, acetone, metha-
nol, water and were screened against nine isolates (7
bacterial and 2 fungal sp.). The details of the plants
along with their voucher number, family name, common
name, parts used, traditional uses and literature source
have been listed in Table 1. The phytochemicals isolated
from ten medicinal plants were containing alkaloids,
amino acids, anthraquinones, cardiac glycosides, flavo-
noids, reducing sugars, resins, saponins, steroids, ter-
penes, tannins, proteins, ph e n o l sa n ds t e r o i d sa ss h o w n
in Table 1.
In the present study the percentage extractive values
were ranged from .05 to 17%. The % extractive value
and yield of extracts was found maximum in methanol
and aqueous extract due to their high polarity and easy
solubility of secondary metabolites in the methanol and
water. The antimicrobial activity of different plant
extract has been listed in Table 2.
The antimicrobial activity different extracts of A.
tenuifolius, A. racemosus, B. aegyptiaca, C. diurnum, C.
dichotoma, E. alba, P. murex, M. koenigii, R. communis
and T. foenum graecum on different bacterial and fungal
clinical isolates has been shown Table 2 as mean ± SE.
S. aureus exhibited good susceptibility to acetone extract
of A. tenuifolius, A. racemosus, C. dichotoma, M. koenigii
and P. murex. S. epidermidis exhibited remarkable sus-
ceptibility to all solvent extract (except acetone) of B.
aegyptiaca. Pet. ether, benzene and chloroform extracts
of B. aegyptiaca and T. foenum graecum revealed signifi-
cant antibacterial activity against P. vulgaris. Our study
revealed P. mirabilis as most resistance bacterial species
due very limited activity observed in all plant extracts.
Out of six solvents, benzene extract of A. tenuifolius, A.
racemosus, E. alba, P. murex R. communis and T. foe-
num graecum exhibited good antibacterial activity
against P. mirabilis.L i k eP. mirabilis, E. coli also found
susceptible to benzene extract of A. racemosus, E. alba,
P. murex and T. foenum graecum. The benzene extracts
of A. racemosus, A. tenuifolius, B. aegyptiaca, E. alba, P.
murex, R. communis and T. foenum graecum also exhibit
very good susceptibility to K. pneumonia. P. aeruginosa
which is considered as very resistance species in infec-
tious diseases was observed 100% susceptible to all sol-
vent extracts of R. communis. Out of selected medicinal
plants A. racemosus exhibited good antifungal activity
against C .a l b i c a n s .A .f u m i g a t u swas found resistant to
B .a e g y p t i a c a ,C .d i u r n u m ,C .d i c h o t o m a ,E .a l b a ,M .
koenigii, R. communis and T. foenum graecum extracts.
In our study the percent activity i.e the total anti-
microbial potency of particular extract was evaluated
from 14.2 to 100%. The acetone extract of A. racemosus
and the Pet. ether of T. foenum graecum showed 100%
activity to all clinical isolates. The present study also
revealed that the P. aeruginosa was highest susceptible
bacteria with 46.6%% susceptibility followed by K. pneu-
monia (40%), S. epidermidis (35%), S. aureus (30%), E.
coli (30%), P. vulgaris (26.6%) and P. mirabilis (20%).
The MIC and MFC of different solvent extracts
against clinical isolates has been listed in Table 3. The
MIC ranges from 31 to 500 μg/ml and similarly the
MFC ranges from 31 to 500 μg/ml. The minimum MIC
(31 μg/ml) of all extracts was observed in the following
way, the acetone extract of A. racemosus against P. vul-
garis and K. pneumonia, the methanolic extract of B.
aegyptiaca and R. communis against K. pneumonia,t h e
aqueous extract of R. communis against P. aeruginosa,
aqueous and methanolic extract of T. foenum- graecum
against P. aeruginosa.
But on the other hand the minimum MFC (31 μg/ml)
was exhibited in acetone extract of A. racemosus against
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zones of inhibitions, was compared with standard com-
mercial available antibiotics such as streptomycin (10
μg/ml) and ketacanzole at (10 μg / m l )o b s e r v e dt h a tt h e
antimicrobial activity of crude extracts was less than
those of the standard drugs.
Discussion
Patients with cancer develop serious bacterial and fungal
infections often, especially during periods of cancer
treatments. Antibiotic usage for the prevention and
treatment of bacterial infections in these high-risk
patients leads to selection pressures resulting in the
emergence and spread of resistant organisms. Many
organisms acquire several resistances mechanisms; mak-
ing them multi-drug-resistant (MDR). The development
of novel antimicrobial agents with activity against patho-
gens that have become resistant to currently available
agents is one tactics for combating resistant organisms
[42]. Therefore the rapid propagation in antibiotic resis-
tance and the increasing interest in natural products
have placed medicinal plants back in the front lights as
Table 1 The summary of medicinal plants and their traditional uses
Botanical name
(Voucher number)/
Local name
Family Traditional uses Organ
tested
Isolated
phytochemicals
Literature
Source
Asphodelus tenuifolius
Cav.
(MDU 6807)/Piyazi
Liliaceae The seeds are generally taken for colds and hemorrhoids, a
febrifuge and also used for rheumatic pain. Seeds are also used as
diuretic agent, healing wound and they are applied externally to
ulcers and for inflamed parts.
FR AL, AN, RS, SA,
TA, ST
[21-23]
Asparagus racemosus
Willd.
(MDU 6806)/Shatavari
Liliaceae The root of the plant is used to promote milk secretion and as
demulcent, diuretic, aphrodisiac, antiseptic antiparasitic, antitumor
and ant diarrhea. It is also used to treat debility, (especially in
women), infertility, impotence, menopause problems, for stomach
ulcers, hyperacidity, dehydration, cough and chronic fevers.
TU AL, SA, TA, FL,
RS, PH, AA
[25,27]
Balanites aegyptiaca L.
(MDU 1601)/Hingote
Balanitaceae The fruit can used to cure mouth ulcer, whooping cough, sleeping
sickness and skin diseases. Fruit kernel has been found as mild
laxatives, antidote to arrow poison, and also act as Vermifuge.
FR AL, CG; FL, RS,
SA, TA, PH
[21,22,24]
Cestrum diurnum L.
(MDU 5112)/Din ka
raja
Solanaceae The leaf paste is used in joint pain. AP SP, AL, RS, OL [22]
Cordia dichotoma G.
Forst (MDU 4801)/
Leswa
Boraginaceae The fruit of the plant is used as antihelminthic, diuretic, purgative,
useful in dry cough, for cure of jaundice, wound purification,
mouth ulcer, and increase male potency.
FR FL, AL, AA, PR [22,25]
Eclipta alba L.
( MDU 3803)/Bhringraj
Asteraceae The whole plant is used particularly for alopecia, ringworm, as a
hair dye, for liver and spleen enlargement, hepatitis, jaundice and
as a general tonic. It has been also used for cataract, cough,
hemorrhage, indigestion, toothache, as an antiseptic and a wound
healing agent.
WP SA, FL, PH, OL,
PR, AA, AD
[25,27]
Murraya koenigii (L.)
Spreng.
( MDU 1505)/Kurry
patte
Rutaceae The leave, bark and the root are used intensively in indigenous
medicine from ancient time, as a tonic for stomachache, stimulant
and carminative. Its leaves are also used in treatment of piles,
headache, stomach ache, influenza, rheumatism, traumatic injury,
insect, snake bites, anti-vomiting, curing dysentery and diarrhea.
Leaves are stimulant and astringent and are used in the treatment
of diarrhea, dysentery and diseases of teeth and gum, useful
against rheumatism, coughs and hysteria.
LE AL, RS, SA TA,
TR, PR
[21,23,26]
Pedalium murex L.
(MDU 5401)/Bada
Gohkru
Pedaliaceae The fruit is used as an aphrodisiac, antiseptic, demulcent, diuretic
and its decoction is also given in incontinence, spermatorrhoea,
nocturnal emission and to promote lochial discharges.
FR SP, AL, FL, TA,
ST, OL, RS, RE
[23,26]
Ricinus communis L.
(MDU 6210)/Arand
Euphorbiaceae The extract of seeds is used internally for acute constipation,
intestinal inflammation, for removal of worms, rheumatism and as
form of birth control. This plant is used as an antidote, bactericide,
expectorant, insecticide, larvicidal, laxative, purgative, tonic, and
Vermifuge. Castor or castor oil is used as ingredient in folk
remedies for abscess, arthritis, asthma, boils, burns, cancer, cold,
colic, convulsions, corns, dermatitis, dog bite etc.
FR AL, FL, PR, ST,
OL, RE
[21,24,25]
Trigonella foenum
graecum L.
(MDU 2418)/Methi
Fabaceae The leaves as a cooked vegetable, is a recommended household
remedy for fever and swelling. It also aids in controlling the cough.
Leaves also tunes up the appetite, improves digestion, eliminates
gaseous distention and relieves the heaviness and abdominal pain.
LE AL, CG, FL, RS,
SA, TA
[21,26]
Abbreviations: FR: fruit; LE: leaves; AL: alkaloid; TA: tannins; FA: fatty acids; PR: proteins; FL: flavonoids; OL: oil; RS: reducing sugars; FL: flavonoids; RE: resins; AD:
aldehyde; SP: saponins; ST: steroids; AA: amino acids; PH: phenols; AN: anthraquinones; ST: steroids; TR: terpenes; CG: cardiac glycosides.
Panghal et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:21
http://www.ann-clinmicrob.com/content/10/1/21
Page 5 of 11Table 2 The inhibition Zone (mm) of antimicrobial medicinal plants against clinical isolates of oral cancer cases
Plant species Fractions extract S. a S. e P. v P. m E. c K. p P. a C. a A. f
A. tenuifolius I 00 0000000
II 0 0 0 10.33 ± 0.5*** 0 10.33 ± 0.5** 0 0 10.66 ± 0.5*
III 0 10.33 ± 0.5** 10.33 ± 0.5*** 10.66 ± 0.5** 11.33 ± 0.5** 15.33 ± 1
NS 11 ± 1.7*** 0 10.33 ± 1.5*
IV 10.33 ± 0.5*** 10.67 ± 0.5*** 0 11 ± 1.7*** 13.33 ± 0.5*** 10.33 ± 0.5* 15.67 ± 1.1* 10.33 ± 1.5
NS 10 ± 0
NS
V 0 11.67 ± 0.5** 10.33 ± 0.5** 10 ± 0* 12.33 ± 1.1** 11 ± 0.57* 0 0 0
V I 00 001 3 . 6 7 ± 0 . 5 * * * 0000
Control 20.66 ± 0.5 20 ± 1 18.33 ± 1 17.33 ± 0.5 16.33 ± 1.1 15.33 ± 1.5 19.33 ± 1.1 10.33 ± 0.5 11 ± 1
A. racemosus I 00 1 2 . 3 3 ± 0 . 5 * * * 000016.66 ± 1.5*** 0
II 0 11.66 ± 0.5*** 0 13.66 ± 1.5** 9 ± 1*** 13.66 ± 1** 12.66 ± 0.5** 10.33 ± 0.5*** 0
III 0 0 0 0 0 11.66 ± 0.5
NS 000
IV 13.66 ± 0.5*** 12.66 ± 0.5*** 14 ± 1.5*** 14.33 ± 0.5*** 15.33 ± 0.5
NS 16.33 ± 1.1 ** 13.33 ± 1.1** 11.66 ± 0.5*** 11.1 ± 1
NS
V 00 00000010.33 ± 0.5
NS
V I 00 9 . 3 3 ± 1 . 5 000013.66 ± 0.5*** 0
Control 18.33 ± 0.5 21.33 ± 2.0 19.33 ± 1 18.33 ± 0.5 14.66 ± 1 18.66 ± 0.5 18.66 ± 0.5 23 ± 0.5 11.66 ± 0.5
B. aegyptiaca I 0 18.33 ± 0.5* 11.66 ± 0.5*** 0 12.33 ± 0.5*** 0 12.33 ± 1.1*** 10.33 ± 1.5*** 0
II 11 ± 0.5*** 20.33 ± 0.5
NS 10.33 ± 0.5*** 0 0 10.66 ± 0.5*** 10 ± 0*** 0 0
III 0 22.33 ± 0.05
NS 12.33 ± 1.5** 0 11.33 ± 0.5*** 11 ± 1*** 13 ± 1.7*** 0 0
I V 00 000016.66 ± 1.1** 0 0
V 10.33 ± 0.5*** 18.33 ± 0.5
NS 0 0 0 18.66 ± 0.5* 11.66 ± 0.5*** 0 0
VI 10 ± 1*** 12.33 ± 0.5** 0 0 10.66 ± 1.1*** 12.33 ± 0.5*** 10.66 ± 1.5*** 0 0
Control 20.33 ± 1 25.33 ± 0.05 18.66 ± 0.5 19 ± 1 14.66 ± 0.5 25.33 ± 0.57 21 ± 1.5 18 ± 1 13.33 ± 0.5
C. diurnum I 00 0000000
I I 00 0000000
I I I 00 0000000
I V 00 0000000
V 00 0000000
V I 01 0 . 6 6 ± 0 . 5 * * 0000000
Control 21.33 ± 1.5 18.66 ± 1.5 19.33 ± 1.5 20 ± 0.5 15.66 ± 1.1 20.33 ± 1.5 17.33 ± 2.0 11.33 ± 1.5 10.33 ± 0.5
C. dichotoma I 1 0 ± 0 . 5 * * 0 0000000
I I 00 0000000
I I I 00 0000000
IV 11.33 ± 0.5** 0 0000000
V 00 0000000
V I 01 0 . 3 3 ± 0 . 5 * * 0000000
Control 18.33 ± 0.5 21.33 ± 2.0 19 ± 1 18.33 ± 0.5 15.33 ± 1 18.33 ± 0.05 18.66 ± 0.08 10.33 ± 0.5 11.33 ± 0.5
E. alba I 0 0 0 0 11.66 ± 1.1*** 10.33 ± 0.5** 10.33 ± 0.5*** 0 0
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1Table 2 The inhibition Zone (mm) of antimicrobial medicinal plants against clinical isolates of oral cancer cases (Continued)
II 0 11.33 ± 0.5*** 0 10.33 ± 0.5*** 11 ± 1*** 12.67 ± 0.5* 0 0 0
III 10.33 ± 0.5*** 10.33 ± 0.5*** 0 0 0 11.66 ± 0.5* 0 12 ± 0
NS 0
IV 0 0 0 0 0 12.66 ± 0.5* 0 0 0
V 00 00001 0 ± 1 * * 13.33 ± 1.1
NS 0
V I 00 000011.33 ± 1.5** 0 0
Control 18.33 ± 0.05 18.66 ± 1.5 17.33 ± 0.5 17.66 ± 0.5 16.66 ± 1.1 20.33 ± 1.5 17 ± 1.7 11.66 ± 1.5 11.33 ± 1.5
M. koenigii I 12 ± 1*** 0 000010.33 ± 0.5** 0 10.33 ± 0.5
NS
II 14.33 ± 0.5** 13.33 ± 0.5** 13.67 ± 0.5*** 14.33 ± 0.5** 13 ± 0.5* 10.33 ± 0.5** 10.67 ± 0.5*** 10.67 ± 0.5
NS 14.33 ± 0.5
NS
III 0 0 0 0 0 10.33 ± 0.5** 0 0 10.67 ± 0.5
NS
IV 14.33 ± 0.5** 14.33 ± 0.5* 14.33 ± 0.5*** 10.33 ± 0.5*** 0 12.67 ± 0.5** 10 ± 0** 10.33 ± 0.5
NS 14.33 ± 0.5
NS
V 00 0000000
V I 00 1 1 . 6 7 ± 0 . 5 * * * 000000
Control 18.66 ± 0.5 19.66 ± 0.5 25.66 ± 1 20.3 ± 0.5 19.66 ± 0.5 15 ± 0.5 19.33 ± 1.1 10.33 ± 0.5 11 ± 1
P. murex I 01 4 . 3 3 ± 0 . 5 * * * 0000000
II 0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
III 14.66 ± 0.5*** 10.33 ± 1*** 0000000
IV 9.66 ± 0.5** 10.66 ± 0.5*** 0 0 10.66 ± 1.1*** 13.33 ± 1.1*** 0 0 0
V I 00 000010.33 ± 0.5*** 9.33 ± 1.5** 0
V 00 00001 2 ± 0 * * 1 1 ± 1 * 8 ± 0 . 5
NS
Control 21.33 ± 1.5 25.33 ± 0.5 19.33 ± 1.5 20.33 ± 0.5 19.33 ± 0.5 2.333 ± 2.6 17.33 ± 2.0 12.66 ± 1.1 10.33 ± 0.5
R. communis I 10.66 ± 1.1*** 0 000010.33 ± 0.5*** 0 -
II 12.33 ± 0.5** 0 10.66 ± 0.5*** 11.66 ± 0.5*** 0 11.33 ± 1.5*** 12.33 ± 1.1*** 0 -
I I I 00 00001 1 ± 1.7*** 0 -
IV 0 0 10.33 ± 1.5*** 0 0 0 12.66 ± 1.5*** 0 -
V 0 0 0 0 12.33 ± 1.1*** 10.33 ± 0.5*** 10 ± 0*** 0 -
VI 0 9.66 ± 0.5** 0 0 14.33 ± 1.1*** 0 16 ± 0.5* 0 -
Control 20.66 ± 1.5 19.66 ± 0.5 19.66 ± 0.5 17.33 ± 0.5 16.33 ± 0.5 20.33 ± 2.0 19.33 ± 1.1 10.33 ± 0.5 11 ± 1
T. foenum graecum I 11 ± 1.1*** 12.33 ± 1
NS 10.67 ± 0.5*** 10.33 ± 0.5** 10.33 ± 1.5*** 11.33 ± 0.5** 10.33 ± 0.5** 0 13.1 ± 1.1
NS
II 13.67 ± 1.5** 11.67 ± 0.5*** 12.33 ± 0.5** 11.66 ± 0.5*** 12.33 ± 0.5*** 10.33 ± 0.5** 0 11.67 ± 0.5
NS 0
III 10.33 ± 0.5** 13.660.5** 12.67 ± 0.5*** 0 10.67 ± 0.5** 10.33 ± 0.5*** 0 10 ± 0.5
NS 0
I V 00 00001 0 ± 0*** 0 0
V 00 000010.33 ± 0.5** 0 0
V I 00 000011.33 ± 0.5** 0 0
Control 18.33 ± 0.5 17.33 ± 0.5 26 ± 1 17.33 ± 0.5 18.33 ± 1 16 ± 2 19.33 ± 1.1 10.33 ± 0.5 11 ± 1
Abbreviations: 0, no activity; S. a, S. aureus;S .e ,S. epidermidis;P .v ,Proteus vulgaris;P .m ,Proteus mirabilis;E .c ,E.coli;K .p ,Klebsiella pneumonia;P .a ,Pseudomonas aeruginosa;C .a ,Candida albicans; A.s Aspergillus
fumigatus; Control, Streptomycin (bacteria), Ketocanozole (fungi); I, Petroleum ether; II, Benzene; III, Chloroform; IV, Acetone; V, Methanol; VI Aqueous; P < .05, less significant*; P < .01, significant**; P < .001, highly
significant***.
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1Table 3 MIC and MFC (μg/ml.) of antimicrobial fractions against clinical isolates of oral cancer cases
Plant species Fractions extract S. a S. e P. v P. m E .c K. p P. a C. a A. f
A. tenuifolius I 0000 00000
II 0 0 0 125 0 500 0 0 250
III 0 250 125 500 250 500 500 0 250
IV 125 125 0 250 250 250 250 125 500
V 0 250 250 250 250 250 0 0 0
VI 0 0 0 0 62.5 0 0 0 0
A. racemosus I 0 0 250 0 0 0 0 125 0
II 0 500 0 125 250 62.5 250 250 0
III 0 0 0 0 0 62.5 0 0 0
IV 125 125 31 125 125 31 250 500 31
V 0 0 0 0 0 0 0 62.5 500
VI 0 0 500 0 0 0 0 0 0
B. aegyptiaca I 0 250 250 0 250 0 62.5 125 0
II 500 125 250 0 0 250 125 0 0
III 0 62.5 125 0 62.5 250 500 0 0
IV 0 0 0 0 0 0 125 0 0
V 250 125 0 0 0 31 62.5 0 0
VI 250 250 0 0 62.5 125 125 0 0
C. diurnum I’ 0000 00000
I I 0000 00000
III 0 0 0 0 0 0 0 0 0
I V 0000 00000
V 0000 00000
VI 0 125 0 0 0 0 0 0 0
C. dichotoma I 250 0 0 0 0 0 0 0 0
I I 0000 00000
III 0 0 0 0 0 0 0 0 0
IV 125 0 0 0 0 0 0 0 0
V 0000 00000
VI 0 125 0 0 0 0 0 0 0
E. alba I 0 0 0 0 250 250 250 0 0
II 0 125 0 125 250 250 0 0 0
III 250 500 0 0 0 500 0 250 0
IV 0 0 0 0 0 250 0 0 0
V 0 0 0 0 0 0 125 250 0
VI 0 0 0 0 0 0 125 0 0
M. koenigii I 250 0 0 0 0 0 250 0 125
II 125 250 125 62.5 125 250 250 125 125
III 0 0 0 0 0 125 0 0 125
IV 62.5 125 31 125 0 62.5 125 125 250
V 0000 00000
VI 0 0 62.5 0 0 0 0 0 0
P. murex I 0 500 0 0 0 0 0 0 0
I I 0000 00000
III 125 125 0 0 0 0 0 0 0
IV 500 250 0 0 125 500 250 0 0
V 0 0 0 0 0 0 125 0 250
VI 0 0 0 0 0 0 0 0 250
R. communis I 250 0 0 0 0 0 500 0 0
II 125 0 125 250 0 500 250 0 0
III 0 0 0 0 0 0 250 0 0
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bial agents and possibly even novel classes of antibiotics
[43]. So in keeping view all the use of medicinal plants
our study was based on isolation of microbes of oral
cancer patients and antimicrobial activity of medicinal
plants against these clinical isolates.
In the present study we found that seeds extract of A.
tenuifolius, the tuber extracts of A. racemosus,f r u i t
extract of B. aegyptiaca, leaves extract of T. foenum-
graecum, showed antibacterial activity against most of
the isolated microbes from the oral cancer cases. The
significant antifungal activity was exhibited by different
extracts of A. racemosus (P < .05) against C. albicans
but in contrast to that no significant antifungal activity
was observed against A. fumigatus.
Although numerous studies have in the past, focused
on antimicrobial activity of A. racemosus, A. tenuifolius,
B .a e g y p t i a c a ,E .a l b a ,P .m u r e x ,R .c o m m u n i sand T.
foenum graecum against various bacteria and fungi
[27,44-46] but very few studies have been focused on
the antimicrobial activity of these medicinal plants
against clinical isolates.
Methanol and water extracts of A. racemosus tubers
were screened against E. coli.S .aureus, K. pneumonia, P.
aeruginosa and C. albicans obtained from R.N.T. Medical
College, Udaipur (Rajasthan). Antimicrobial activity was
observed against all the studied microbes with inhibition
zone range from 7 to 24 mm [47]. On the contrary we
have not observed antibacterial activity against E. coli, S.
aureus, K. pneumonia and P. aeruginosa.A n o t h e rs t u d y
the showed the antifungal activity of tubers methanol
extract against C. albicans (16 mm) isolated from vaginal
thrush patients, visiting Rajah Muthiah Medical College
and Hospital, Annamalai Nagar, Tamilnadu, India [48].
Our study revealed the almost similar antifungal activity
of A. racemosus tubers against C. albicans (13 mm).
The methanol and ethanol leaf extracts of E. alba was
evaluated for the antimicrobial activity against human
isolated pathogens (E. coil, K. pneumonia, S. aureus and
P. aeruginosa ) obtained from Department Microbiology,
Mysore Medical College and Research Institute, Rajiv
Gandhi University, Mysore, India [49]. It was observed
that both extracts exhibited antibacterial activity against
all bacteria and inhibition zone was observed ranged
from 9 to 20 mm. But in contrast to above study we
found that methanol and aqueous extract of E. alba
have no inhibition against E. coli, K. pneumonia and S.
aureus but activity was only found against P. aeruginosa
(10 mm, 11 mm).
To a large extent, the chronological age of the plant,
percentage humidity of the harvested material, situation
and time of harvest, solvent used and the method of
extraction were possible sources of variation for the
bioactivity of the extracts [50-52].
As it is well known that P. aeruginosa is notorious for
its resistance to antibiotics and is, therefore particularly
dangerous and dreaded pathogen. The bacterium is
naturally resistance to many antibiotics due to the per-
meability barriers afforded by its outer membrane com-
posed of lipopolysaccharide (LPS). Also, its tendency to
colonize surfaces in a biofilm form makes the cells
impervious to therapeutic concentrations of antibiotics.
One method to reduce the resistance to antibiotics is by
using antibiotics resistance inhibitors from plant origin
[53,54]. We have observed very significant (P < .05) anti-
bacterial activity of B. aegyptiaca and R. communis all
extracts, against P. aeruginosa.T h e s er e s u l t sr e v e a l e d
that the antibacterial activity of R. communis and B.
aegyptiaca extracts hold the most promise for further
work against this bacterium through toxicity testing.
In our study various phytochemicals compounds alka-
loids, amino acids, anthraquinones, cardiac glycosides,
flavonoids, reducing agents, resins, saponins, terpenes,
tannins, proteins, phenols and steroids were isolated
from ten medicinal plants. The antimicrobial susceptibil-
ity of studied medicinal plants could be attributed to the
presence of these antimicrobial compounds, which is
also proved by other studies [55-62].
The results of our research highlights, the fact that the
organic solvent extracts exhibited greater antimicrobial
Table 3 MIC and MFC (μg/ml.) of antimicrobial fractions against clinical isolates of oral cancer cases (Continued)
IV 0 0 250 0 0 0 250 0 0
V 0 0 0 0 250 31 250 0 0
VI 0 62.5 0 0 250 0 31 0 0
T. foenum-graecum I 31 250 250 250 125 62.5 125 0 125
II 62.5 31 125 125 31 31 0 125 0
III 125 62.5 125 0 250 125 0 125 0
IV 0 0 0 0 0 0 62.5 0 0
V 0000 003 1 00
V I 0000 003 1 00
Abbreviations: 0, no activity; S. a: S. aureus;S .e :S. epidermidis;P .v :Proteus vulgaris;P .m :Proteus mirabilis;E .c :E.coli;K .p :Klebsiella pneumonia;P .a :Pseudomonas
aeruginosa;C .a :Candida albicans; A.s: Aspergillus fumigatus; Control, Streptomycin (bacteria), Ketocanozole (fungi); I: Petroleum ether; II: Benzene; III: Chloroform;
IV: Acetone; V: Methanol; VI: Aqueous.
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polar or non-polar and they were extracted only through
the organic solvent medium [63,64]. So the present
observation suggests that the organic solvent extraction
was suitable to verify the antimicrobial properties of
medicinal plants which are also supported by many
other investigators [65-68].
In nut shell, our study justifies the claimed uses of A.
tenuifolius, A. racemosus, B .a e g y p t i a c a ,E .a l b a ,P .
murex, M. koenigii, R. communis and T. foenum graecum
in the Indian traditional system of medicine to treat var-
ious diseases. However, as the toxic affects of plant
extracts were not explored or tested in present study, so
the usefulness of these extracts as antimicrobial com-
pound can only be predicated after toxicity testing on
eukaryotic cells.
Conclusion
The present investigation reported that the secondary
infections in the immunocompromised oral cancer cases
were due to bacterial and fungal species. This study also
report that the medicinal plants (A. tenuifolius, A. race-
mosus, B. aegyptiaca, E. alba, P. murex, M. koenigii, R.
communis and T. foenum graecum)u s e di nI n d i a n - h e r -
bal medicine may possess antimicrobial activity against
the clinical isolates of oral cancer cases. These findings
can form the basis for further studies to toxicity testing,
isolate active compounds, elucidate the structures, and
also evaluate them against wider range of resistance bac-
terial and fungal strains of cancer patients with the goal
to find new therapeutic principles.
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